Sato et al. reported that high expression of CD147 in renal cell carcinoma (RCC) is associated with resistance to the anti-tyrosine kinase receptor inhibitor, sunitinib, suggesting therefore that CD147 blockage in association to tyrosine kinase receptors inhibitors could restore sensitivity to such targeted therapy in RCC [110]. Here, BSG is linked to hereditary clear cell renal cell carcinoma.